Analyst Ratings For Aridis Pharmaceuticals Inc (NASDAQ:ARDS)
Today, Northcoast Research initiated coverage on Aridis Pharmaceuticals Inc (NASDAQ:ARDS) with a Outperform with a price target of $40.00.
There are 4 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Aridis Pharmaceuticals Inc (NASDAQ:ARDS) is Buy with a consensus target price of $29.3333 per share, a potential 141.43% upside.
Some recent analyst ratings include
- 9/10/2018-Aridis Pharmaceuticals Inc (NASDAQ:ARDS) has coverage initiated with a Outperform rating and $40.00 price target
- 9/10/2018-Aridis Pharmaceuticals Inc (NASDAQ:ARDS) has coverage initiated with a Outperform rating
- 9/10/2018-Aridis Pharmaceuticals Inc (NASDAQ:ARDS) has coverage initiated with a Buy rating and $23.00 price target
- 9/10/2018-Aridis Pharmaceuticals Inc (NASDAQ:ARDS) has coverage initiated with a Overweight rating
Recent Trading Activity for Aridis Pharmaceuticals Inc (NASDAQ:ARDS)
Shares of Aridis Pharmaceuticals Inc closed the previous trading session at 12.38 up +0.27 2.19% with 11162 shares trading hands.